Susquehanna Fundamental Investments LLC Invests $5.65 Million in Qiagen (NYSE:QGEN)

Susquehanna Fundamental Investments LLC purchased a new position in Qiagen (NYSE:QGEN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 126,777 shares of the company's stock, valued at approximately $5,645,000. Susquehanna Fundamental Investments LLC owned approximately 0.06% of Qiagen as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Groupama Asset Managment boosted its position in shares of Qiagen by 8,074.0% in the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Qiagen by 9.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after purchasing an additional 2,202,040 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Qiagen by 2.5% in the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock worth $970,534,000 after purchasing an additional 531,362 shares in the last quarter. Vanguard Group Inc. raised its holdings in Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after acquiring an additional 77,119 shares during the last quarter. Finally, Norges Bank purchased a new position in Qiagen in the 4th quarter worth approximately $181,529,000. 70.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on QGEN. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Robert W. Baird boosted their price objective on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Morgan Stanley restated an "equal weight" rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. UBS Group decreased their price objective on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Finally, Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $47.83.

Qiagen Trading Down 2.2 %

Shares of QGEN stock opened at $42.10 on Monday. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30. The firm has a fifty day moving average price of $39.95 and a 200-day moving average price of $41.71. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company has a market cap of $9.36 billion, a price-to-earnings ratio of 117.23, a PEG ratio of 2.39 and a beta of 0.62.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, equities analysts predict that Qiagen will post 2.26 earnings per share for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.